C
Cofactor Genomics
Biotech & Life Sciences · San Francisco, United States · Founded 2008
Cofactor Genomics uses RNA to diagnose disease MoreLess
Cofactor Genomics specializes in precision medicine by leveraging RNA sequencing and advanced machine learning algorithms to develop multidimensional models of disease. The company focuses on identifying powerful biomarkers that can predict patient responses to treatments, particularly in the field of immunotherapy. Operating in the biotechnology and healthcare sectors, Cofactor Genomics serves pharmaceutical companies, research institutions, and clinical laboratories. Its business model revolves around providing RNA profiling services and predictive immune modeling solutions, which are critical for developing personalized treatment plans. Revenue is generated through service contracts, clinical study collaborations, and partnerships with healthcare providers.
Keywords: RNA sequencing, precision medicine, machine learning, biomarkers, immunotherapy, predictive modeling, healthcare, biotechnology, clinical studies, personalized treatment.
Company overview
Cofactor Genomics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2008
- Headquarters
- San Francisco, United States
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 76.7
Valuation & funding
Cofactor Genomics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Dec 2025 | $0 | — | LabCorp · Ascension | ↗ |
| EARLY VCEquity / VC | Dec 2021 | $6.9M | $28M | Undisclosed | — |
| SERIES A✓Equity / VC | Sep 2017 | $18M | $72M | Ascension · Refactor Capital · Y Combinator · iSelect Fund | — |
| Other✓Other financing | Sep 2015 | $0 | — | 7percent Ventures | — |
| SEED✓Equity / VC | Sep 2015 | $125K | $500K | Y Combinator | — |
| GRANTOther financing | Jun 2010 | Undisclosed | — | ||
| SPINOUT✓Other financing | Jan 2008 | Washington University in St. Louis | — | ||
| ANGEL✓Equity / VC | Jan 2008 | Undisclosed | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 13 |
| 2025 | 11 |
| 2024 | 9 |
| 2023 | 12 |
| 2022 | 13 |
| 2021 | 15 |
| 2020 | 19 |
Growth signals
Cofactor Genomics website traffic
Latest recorded traffic for Cofactor Genomics is 2.8K monthly website visits, down 22.2% over the last three months. Cofactor Genomics's team grew 9.1% over the past year.
Comparisons
Cofactor Genomics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Cofactor Genomics's talent
Source: Dealroom Talent Intelligence.
Investors
20 investors on Cofactor Genomics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Cofactor Genomics has talent and traffic
team presence
In the news
Latest news about Cofactor Genomics
Recent press, funding announcements, and product moves mentioning Cofactor Genomics — open to read from the original sources.
Market sentiment
What the market is saying about Cofactor Genomics
An AI-synthesized read of the highest-engagement posts about Cofactor Genomics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cofactor Genomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.